Protagonist Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

PTGX$135.90+2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)


· · Three Months Ended · · Nine Months Ended
· · September 30, · · September 30,
· 2024 · 2023 · 2024 · 2023
License and collaboration revenue	$4,675	$—	$263,795	$—
Operating expenses:
Research and development	35,970	30,664	103,224	91,262
General and administrative	10,158	7,662	34,508	25,439
Total operating expenses	46,128	38,326	137,732	116,701
Income (loss) from operations	(41,453)	(38,326)	126,063	(116,701)
Interest income	7,682	4,252	19,462	10,656
Other income (expense), net	141	(31)	219	(245)
Income (loss) before income tax benefit (expense)	(33,630)	(34,105)	145,744	(106,290)
Income tax benefit (expense)	420	—	(2,230)	—
Net income (loss)	$(33,210)	$(34,105)	$143,514	$(106,290)
Net income (loss) per share, basic	$(0.54)	$(0.58)	$2.34	$(1.91)
Net income (loss) per share, diluted	$(0.54)	$(0.58)	$2.22	$(1.91)
Weighted-average shares used to compute net income (loss) per share, basic	61,767,934	59,182,899	61,311,310	55,542,543
Weighted-average shares used to compute net income (loss) per share, diluted	61,767,934	59,182,899	64,611,941	55,542,543

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.